<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="51597">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02434484</url>
  </required_header>
  <id_info>
    <org_study_id>B0501-M065-501</org_study_id>
    <nct_id>NCT02434484</nct_id>
  </id_info>
  <brief_title>Symbenda Post-Marketing Surveillance (PMS)</brief_title>
  <official_title>Post-Marketing Surveillance of Symbenda Injection (Bendamustine Hydrochloride) in Korean Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Korea Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <brief_summary>
    <textblock>
      This is a PMS of Symbenda Injection (bendamustine hydrochloride) in Korean Patients. The
      main objective is to obtain safety information related to Symbenda treatment from clinical
      practice.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 2017</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">June 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of Symbenda as a measure of number of participants with adverse events/serious adverse events/adverse drug reactions</measure>
    <time_frame>Up to 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Non-Hodgkin's lymphomas response rate per Standardize Response Criteria for Non-Hodgkin's lymphomas to assess the tumor response</measure>
    <time_frame>After 2nd cycle (each cycle = 28 days) up to 1.5 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chronic lymphocytic leukemia response rate per National Cancer Institute-Sponsored Working Group (NCISWG) criteria to assess the tumor response</measure>
    <time_frame>After 2nd cycle (each cycle = 28 days) up to 2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multiple myeloma response rate per International Myeloma Working Group (IMWG) uniform response criteria to assess the tumor response</measure>
    <time_frame>After 2nd cycle (each cycle = 28 days) up to 2 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Lymphoma, Non-Hodgkin</condition>
  <condition>Lymphocytic Leukemia</condition>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Symbenda</arm_group_label>
    <description>Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda will be enrolled in the study.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda
        will be enrolled in the study.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Subjects who are prescribed with Symbenda per approved prescribing information of Symbenda
        will be enrolled in the study.

        This study will be conducted as complete surveillance method; subjects who meet the
        inclusion/exclusion criteria and administrate Symbenda for the first time after conclusion
        of agreement will be enrolled.

        Inclusion Criteria:

        Patients who meet the following criteria will be eligible for inclusion in the study:

          1. Patients with approved indication for Symbenda in Korea

          2. Patients who have verbal or written consent for use of personal and medical
             information for the study purpose Investigators will refer to approved indications
             and contraindications regarding inclusion criteria.

        Exclusion Criteria:

        Investigators will refer to approved indications and contraindications regarding exclusion
        criteria.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Youngji Pyo</last_name>
    <email>y-pyo@eisaikorea.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chungcheongbuk-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Chungcheongnam-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeongji-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeongsanbuk-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Gyeongsangnam-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeollabuk-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Jeollanam-do</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>March 6, 2017</lastchanged_date>
  <firstreceived_date>April 28, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Symbenda</keyword>
  <keyword>Non-Hodgkin's lymphomas</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Multiple myeloma</keyword>
  <keyword>Bendamustine Hydrochloride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bendamustine Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
